DRKS00007554已完成不适用
Follow-up Assessment of the Midterm Efficacy of the Home Visiting Program Pro Kind Based on a Randomized Controlled Trial
Kriminologisches Forschungsinstitut Hannover0 个研究点目标入组 755 人开始时间: 2015年6月11日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 755
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- one 至 one（—）
- 性别
- Female
入选标准
- •Participation in the first stage of the Pro Kind evaluation. Resident in Germany. (In the first program stage Pro Kind intervention registered only financially or socially disadvantaged first-time mothers during their 12th to 28th weeks of pregnancy. Financial disadvantage is defined as receipt of social welfare benefits, unemployment compensation, an income that is as low as social welfare benefits, and/or over-indebtedness. The considered social risk factors included, for example, low education, teenage pregnancy, social isolation, violent experiences, and health problems.)
排除标准
- •Insufficient knowledge of German language, without permanent residence permission.
研究者
相似试验
已完成
Unknown
Evaluation of long-term safety and efficacy after neuroprotective gene therapy with SIV-hPEDF for retinitis pigmentosaRetinitis PigmentosaJPRN-UMIN000049825Kyushu University10
招募中
Unknown
Follow-up study of the long-term efficacy and safety of investigator-initiated clinical trials (HUCV002-01-02 study and HUCV002-01-03 study) of intravenous HUCV002-01 in patients with chronic heart failure (HUCV002-01-02 study and HUCV002-01-03 study)chronic heart failureJPRN-jRCT1070220091Ide Tomomi30
已完成
不适用
Evaluation of the acute- and long-term results after endovascular therapy of the popliteal arteryI70.22DRKS00019096niversitäts-Herzzentrum Bad Krozingen378
进行中（未招募）
1 期
A Follow-Up Study of Long-Term Efficacy of Patients with HER2-Positive Early Breast Cancer Who Had Been Enrolled in Study CT-P6 3.2ong-term safety and efficacy of treatment with CT-P6 (Herzuma) in HER-2 positive early breast cancer patientsEUCTR2019-003518-15-ROCelltrion, Inc.216
进行中（未招募）
1 期
A Follow-Up Study of Long-Term Efficacy of Patients with HER2-Positive Early Breast Cancer Who Had Been Enrolled in Study CT-P6 4.2ong-term safety and efficacy of treatment with CT-P6 (Herzuma) in HER-2 positive early breast cancer patientsEUCTR2019-003518-15-PLCelltrion, Inc.350